Imatinib and norimatinib

Imatinib by LC-MS/MS
Clinical details: 
Imatinib is now first-line treatment for chronic phase chronic myeloid leukaemia (CML). Imatinib has also proved successful in treating gastrointestinal stromal tumours (GIST). N-Desmethylimatinib (norimatinib) is the principal plasma metabolite of imatinib and accumulates to concentrations of approximately 20 % of those of imatinib during chronic therapy. It may possess pharmacological activity. Treatment failure has been attributed to poor adherence, inadequate dosage, or development of a mutation causing imatinib resistance. Thus, monitoring plasma imatinib and norimatinib may help in assessing adherence and in optimising treatment. Cytogenetic and molecular responses to imatinib have been associated with pre-dose plasma imatinib concentrations of 1 mg/L or more. In GIST a threshold for response of 1.1 mg/L has been suggested.
Sample type and Volume required: 
2mL EDTA whole blood or 1 mL plasma or serum (pre-dose or ‘trough’ sample).
Turnaround time: 
5 working days
Storage and transport: 
Please refrigerate (if possible) if not sending immediately. Send by first class post.
Toxicology Department at King's Hospital
020 3299 5881
King's College Hospital
Bessemer Wing - 3rd Floor
Denmark Hill
London SE5 9RS
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 03/10/2022